JPWO2021216899A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216899A5 JPWO2021216899A5 JP2022563172A JP2022563172A JPWO2021216899A5 JP WO2021216899 A5 JPWO2021216899 A5 JP WO2021216899A5 JP 2022563172 A JP2022563172 A JP 2022563172A JP 2022563172 A JP2022563172 A JP 2022563172A JP WO2021216899 A5 JPWO2021216899 A5 JP WO2021216899A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- less
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- 150000001413 amino acids Chemical group 0.000 claims 16
- 241001465754 Metazoa Species 0.000 claims 12
- 102000003816 Interleukin-13 Human genes 0.000 claims 11
- 108090000176 Interleukin-13 Proteins 0.000 claims 11
- 102000004388 Interleukin-4 Human genes 0.000 claims 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 10
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 claims 9
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 claims 9
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 6
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 6
- 241000283073 Equus caballus Species 0.000 claims 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 4
- 238000012575 bio-layer interferometry Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 241000282326 Felis catus Species 0.000 claims 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 238000010494 dissociation reaction Methods 0.000 claims 3
- 230000005593 dissociations Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004850 protein–protein interaction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 229940126638 Akt inhibitor Drugs 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 229940126560 MAPK inhibitor Drugs 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000007781 signaling event Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014090P | 2020-04-22 | 2020-04-22 | |
| US63/014,090 | 2020-04-22 | ||
| US202063014573P | 2020-04-23 | 2020-04-23 | |
| US63/014,573 | 2020-04-23 | ||
| PCT/US2021/028679 WO2021216899A1 (en) | 2020-04-22 | 2021-04-22 | Il4/il13 receptor molecules for veterinary use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522676A JP2023522676A (ja) | 2023-05-31 |
| JPWO2021216899A5 true JPWO2021216899A5 (pt) | 2024-05-02 |
Family
ID=78270112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563172A Pending JP2023522676A (ja) | 2020-04-22 | 2021-04-22 | 動物用のｉｌ４／ｉｌ１３受容体分子 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4139344A1 (pt) |
| JP (1) | JP2023522676A (pt) |
| KR (1) | KR20230005880A (pt) |
| CN (1) | CN116034112A (pt) |
| AU (1) | AU2021259785A1 (pt) |
| BR (1) | BR112022021204A2 (pt) |
| CA (1) | CA3173927A1 (pt) |
| MX (1) | MX2022013149A (pt) |
| WO (1) | WO2021216899A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| JP2020517262A (ja) | 2017-04-21 | 2020-06-18 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023289A1 (en) * | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| JP2020517262A (ja) * | 2017-04-21 | 2020-06-18 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
-
2021
- 2021-04-22 CN CN202180036305.6A patent/CN116034112A/zh active Pending
- 2021-04-22 KR KR1020227040170A patent/KR20230005880A/ko active Search and Examination
- 2021-04-22 AU AU2021259785A patent/AU2021259785A1/en active Pending
- 2021-04-22 EP EP21793671.5A patent/EP4139344A1/en active Pending
- 2021-04-22 CA CA3173927A patent/CA3173927A1/en active Pending
- 2021-04-22 BR BR112022021204A patent/BR112022021204A2/pt unknown
- 2021-04-22 JP JP2022563172A patent/JP2023522676A/ja active Pending
- 2021-04-22 WO PCT/US2021/028679 patent/WO2021216899A1/en unknown
- 2021-04-22 MX MX2022013149A patent/MX2022013149A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11319355B2 (en) | Engineered IL-2 Fc fusion proteins | |
| Silacci et al. | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency | |
| JP2020517262A5 (pt) | ||
| AU2003284895B2 (en) | IL-1 receptor based antagonists and methods of making and using | |
| CN113194984A (zh) | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 | |
| JP2012515556A5 (pt) | ||
| JP2008511337A5 (pt) | ||
| JPH0429997A (ja) | ヒトｇｐ１３０蛋白質 | |
| KR20120046274A (ko) | 항체 생성의 최적화 방법 | |
| JP2023078158A (ja) | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 | |
| JP2009541274A5 (pt) | ||
| WO2020139984A1 (en) | Igg fc variants for veterinary use | |
| Patel et al. | Sequence of the dog immunoglobulin alpha and epsilon constant region genes | |
| CN110573626A (zh) | 抗体选择方法 | |
| KR20230005880A (ko) | 수의학적 사용을 위한 il4/il13 수용체 분자 | |
| Fiedler et al. | Use of thiophilic adsorption chromatography for the one-step purification of a bacterially produced antibody Fab fragment without the need for an affinity tag | |
| JPWO2021216899A5 (pt) | ||
| RU2009126545A (ru) | МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН | |
| CN116769027A (zh) | 一种抗il-17纳米抗体、多肽及其应用 | |
| KR102018608B1 (ko) | 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법 | |
| CN111909268A (zh) | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 | |
| CN112262213A (zh) | 新型抗pad2抗体 | |
| WO2021251438A1 (ja) | エリスロポエチンポリペプチドを含む融合タンパク質 | |
| CN117866103A (zh) | 一种抗破伤风双特异性抗体及其制备方法与应用 | |
| CN111909267A (zh) | 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用 |